LOS ANGELES, Dec. 07, 2022 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ:VS) today announced the pricing of its public offering of 2,100,000 units for gross proceeds of approximately $2.1 million, before deducting placement agent fees and other offering expenses payable by Versus. Each unit consists (i) of either (a) one common share or (b) one pre-funded warrant to purchase one common share and (ii) two warrants to purchase one common share each, at a public offering price of $1.00 per unit. The warrants will have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. All of the shares, pre-funded warrants and warrants included in this offering are being sold by Versus. The offering is expected to close on December 9, 2022, subject to customary closing conditions.
IMUNON Enters Into Technology Evaluation Agreement With Acuitas Therapeutics To Evaluate IMUNON’s PLACCINE Plasmid DNA With Acuitas’ Lipid Nanoparticle Delivery System
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, and Acuitas Therapeutics, a private biotechnology company focused on the development of delivery systems for nucleic acid vaccines and therapeutics
